by Elena Iemma | Feb 22, 2024 | Thinking Out Loud -Blog
Immunogenicity assessment is key to drug safety. Currently there is no standard approach to the In Silico Immunogenicity Assessment of Therapeutic Peptides, however, the EpiVax team has worked with the FDA to develop several methods, including a validated in silico...
by Riley Nolan | Aug 22, 2022 | Featured, Thinking Out Loud -Blog
After almost three year of virtual meetings, EpiVax is back on the road in earnest this fall! We are so excited to reconnect in person with our clients, partners and friends around the globe. And this fall we have an ambitious travel schedule! Check out the list...
by Riley Nolan | Nov 4, 2021 | Featured, News
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) is pleased to announce an important commercial licensing agreement with Maruho Co., Ltd. (“Maruho”) for EpiVax’s patented Tregitope technology. This marks an exciting step for Maruho and...
by Riley Nolan | Aug 31, 2021 | Featured, Thinking Out Loud -Blog
From Disco to BTS Time flies when you are having fun! I totally missed the 10th anniversary of “Thinking Out Loud” a.k.a TOL – this newsletter. Do you want to see the first post? I hope you like disco! Lucky for you, I’ve moved on...
by Riley Nolan | Jul 28, 2021 | Featured, Thinking Out Loud -Blog
(Delta) Variants at the Gates Been to the Disco lately? In the Netherlands, dancing is fueling a new wave of COVID infections. You can’t ignore the rise of COVID-19 cases globally after the Delta variant began circulating widely in June. Our hearts go out to...